Hepion Pharmaceuticals stock trades at USD 0.07 after Nasdaq delisting

Published on 09/25/2026 at 17:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hepion Pharmaceuticals reported USD 1,628,625 in cash for Q2 2026 after its move to OTCQB. Operating cash flow was negative USD 1,393,955 in the same period.

HEPA, US4268971032, Illustration mit AI erstellt.

Hepion Pharmaceuticals stock (ISIN US4268971032) was trading at USD 0.07 on OTCQB on September 25, 2026 at 10:34 a.m. ET, giving the company a market capitalization of USD 866,758. The latest financing and corporate-action filings put liquidity and future share issuance at the center of the investment case.

Financing adds debt and warrants

According to Stock Titan, Hepion entered into the financing on September 3, 2026, with Gravitas Capital LP receiving a USD 500,000 secured convertible note and warrants for 12,500,000 common shares. The note carries 8% annual interest payable in kind, matures on September 3, 2027, and has a conversion price of USD 0.04 per share, while the warrants carry a USD 0.06 exercise price.

The financing is secured by all of Hepion's assets. The warrants expire on September 3, 2031, and both the conversion right and warrant exercise depend on stockholder approval of an increase in authorized common shares.

Q2 cash burn sets the frame

For the second quarter ended June 30, 2026, Hepion reported revenue of USD 0, a net loss of USD 1,248,237 and diluted EPS of negative USD 0.08, according to Stock Titan. Cash and equivalents stood at USD 1,628,625, compared with operating cash outflow of USD 1,393,955 in the same quarter.

That comparison makes the financing material: the reported cash balance was only 1.17 times the second-quarter operating cash outflow. The filing also presents the balance as equivalent to 106.3 days of operating cash use, linking the new capital directly to near-term liquidity.

Share capacity expands sharply

A definitive information statement dated September 10, 2026, reviewed by Stock Titan, describes approval for authorized common shares to rise from 120,000,000 to 750,000,000. The same filing authorizes a reverse split between 1-for-20 and 1-for-50, with the board choosing the ratio and timing.

The filing lists 98,220,476 common shares outstanding as of August 31, 2026 and raises the 2023 equity-plan reserve from 8,000,000 to 18,000,000 shares. These actions expand potential issuance capacity while the financing documents already include 12,500,000 warrant shares.

OTCQB price stays below yearly high

The USD 0.07 intraday price on September 25, 2026, stood 36.36% below the 52-week high of USD 0.11 and 133.33% above the 52-week low of USD 0.03. Trading volume was 2,001 shares at the quoted time.

For investors, the key figures are the financing terms, the second-quarter cash burn and the scale of the approved share-capacity increase. The capital structure now matters as much as the clinical-stage biotechnology story.

HEPA stock facts remain highly diluted

Hepion Pharmaceuticals stock was trading at USD 0.07 on OTCQB on September 25, 2026 at 10:34 a.m. ET. The 52-week range was USD 0.03 to USD 0.11, while market capitalization was USD 866,758.